Wall Street brokerages expect Intellia Therapeutics, Inc. (NASDAQ:NTLA) to report sales of $8.60 million for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest sales estimate coming in at $4.67 million and the highest estimate coming in at $15.22 million. Intellia Therapeutics posted sales of $22.22 million during the same quarter last year, which would indicate a negative year over year growth rate of 61.3%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 4th.
On average, analysts expect that Intellia Therapeutics will report full-year sales of $30.49 million for the current fiscal year, with estimates ranging from $13.00 million to $49.99 million. For the next financial year, analysts anticipate that the firm will report sales of $43.22 million, with estimates ranging from $22.80 million to $70.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.40). Intellia Therapeutics had a negative return on equity of 39.01% and a negative net margin of 442.58%. The company had revenue of $6.55 million for the quarter, compared to analyst estimates of $12.21 million. During the same period in the prior year, the business earned ($0.61) earnings per share. Intellia Therapeutics’s revenue was down 59.7% on a year-over-year basis.
Intellia Therapeutics stock traded up $6.27 during mid-day trading on Monday, hitting $131.62. 26,922 shares of the company’s stock were exchanged, compared to its average volume of 1,630,194. The stock has a market cap of $9.67 billion, a P/E ratio of -46.47 and a beta of 2.14. The stock has a 50 day moving average of $151.06 and a two-hundred day moving average of $115.14. Intellia Therapeutics has a 1-year low of $22.17 and a 1-year high of $202.73.
In other news, EVP Laura Sepp-Lorenzino sold 26,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 4th. The shares were sold at an average price of $138.24, for a total transaction of $3,594,240.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Lebwohl sold 2,400 shares of the business’s stock in a transaction that occurred on Monday, August 9th. The shares were sold at an average price of $164.05, for a total value of $393,720.00. Following the completion of the transaction, the executive vice president now directly owns 3,191 shares in the company, valued at approximately $523,483.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 294,803 shares of company stock worth $45,679,690. 3.90% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics in the second quarter valued at $32,000. Itau Unibanco Holding S.A. acquired a new position in Intellia Therapeutics in the second quarter worth about $47,000. Sterling Investment Advisors Ltd. bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $49,000. Rockefeller Capital Management L.P. increased its position in Intellia Therapeutics by 67.8% in the first quarter. Rockefeller Capital Management L.P. now owns 626 shares of the company’s stock worth $50,000 after buying an additional 253 shares during the period. Finally, Bbva USA bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $77,000. Hedge funds and other institutional investors own 84.32% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
Further Reading: Capital gains and your 401(k) or IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.